These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38543552)

  • 21. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
    Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
    mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
    Upasani V; Townsend K; Wu MY; Carr EJ; Hobbs A; Dowgier G; Ragno M; Herman LS; Sharma S; Shah D; Lee SFK; Chauhan N; Glanville JM; Neave L; Hanson S; Ravichandran S; Tynan A; O'Sullivan M; Moreira F; Workman S; Symes A; Burns SO; Tadros S; Hart JCL; Beale RCL; Gandhi S; Wall EC; McCoy L; Lowe DM
    Clin Infect Dis; 2023 Oct; 77(7):950-960. PubMed ID: 37338118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
    Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
    Liao BH; Platen L; Grommes M; Cheng CC; Holzmann-Littig C; Christa C; Haller B; Kappler V; Bester R; Werz ML; Platen E; Eggerer P; Tréguer L; Küchle C; Schmaderer C; Heemann U; Renders L; Protzer U; Braunisch MC
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants.
    Egia-Mendikute L; Bosch A; Prieto-Fernández E; Vila-Vecilla L; Zanetti SR; Lee SY; Jiménez-Lasheras B; García Del Río A; Antoñana-Vildosola A; de Blas A; Velasco-Beltrán P; Serrano-Maciá M; Iruzubieta P; Mehrpouyan M; Goldberg EM; Bornheimer SJ; Embade N; Martínez-Chantar ML; López-Hoyos M; Mato JM; Millet Ó; Palazón A
    Front Immunol; 2022; 13():1014309. PubMed ID: 36505411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.
    Manu AA; Owusu IA; Oyawoye FO; Languon S; Barikisu IA; Tawiah-Eshun S; Quaye O; Donkor KJ; Paemka L; Amegatcher GA; Denyoh PMD; Oduro-Mensah D; Awandare GA; Quashie PK
    Heliyon; 2024 May; 10(10):e31392. PubMed ID: 38826759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection.
    Reinholm A; Maljanen S; Jalkanen P; Altan E; Tauriainen S; Belik M; Skön M; Haveri A; Österlund P; Iakubovskaia A; Pasternack A; Naves RA; Ritvos O; Miettinen S; K Häkkinen H; Ivaska L; Tähtinen PA; Lempainen J; Kantele A; Kakkola L; Julkunen I; Kolehmainen P
    Commun Med (Lond); 2024 Feb; 4(1):28. PubMed ID: 38396065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay.
    Almahboub SA; Algaissi A; Alfaleh MA; ElAssouli MZ; Hashem AM
    Front Microbiol; 2020; 11():2020. PubMed ID: 33013745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference.
    Graninger M; Jani CM; Reuberger E; Prüger K; Gaspar P; Springer DN; Borsodi C; Weidner L; Rabady S; Puchhammer-Stöckl E; Jungbauer C; Höltl E; Aberle JH; Stiasny K; Weseslindtner L
    Microbiol Spectr; 2023 Feb; 11(1):e0231422. PubMed ID: 36622205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
    Plested JS; Zhu M; Cloney-Clark S; Massuda E; Patel U; Klindworth A; Massare MJ; Cai R; Fries L; Glenn G; Kalkeri R
    Microorganisms; 2023 Feb; 11(2):. PubMed ID: 36838333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.